Stryker Corp. (SYK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1161134,
    "name": "Stryker Corp.",
    "stock_name": "Stryker Corp.",
    "full_name": "Stryker Corp.",
    "name_url": "stocks-analysis/stryker-corp",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "364.35",
    "chg": -1.6,
    "chgp": "-0.44%",
    "dir": -1,
    "prev_price": "365.95",
    "mcapval": "150,288.82",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US8636671013",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "963.98 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/stryker-corp-1161134-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Stryker Corp. Hits Day Low of $355.75 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stryker-corp-hits-day-low-of-35575-amid-price-pressure-3667361",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/StrykerCorp_priceRelatedfactors_3667361.png",
        "date": "2025-11-03 17:36:31",
        "description": "Stryker Corp. faced a significant stock price decline today, marking a challenging trading session. Over the past week and month, the company has experienced notable decreases, contrasting with modest gains in the S&P 500. Despite these challenges, Stryker maintains a strong financial position and robust institutional holdings."
      },
      {
        "title": "Stryker Corp. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stryker-corp-valuation-grade-downgraded-from-very-expensive-to-expensive-3649097",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StrykerCorp_valuationdot_3649097.png",
        "date": "2025-10-27 15:58:33",
        "description": "Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a Price to Book Value of 7.01. Key financial metrics include an EV to EBIT of 31.29 and a PEG ratio of 1.86, reflecting strong operational efficiency and competitive positioning within the industry."
      },
      {
        "title": "Is Stryker Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stryker-corp-overvalued-or-undervalued-3637559",
        "imagepath": "",
        "date": "2025-10-21 12:04:42",
        "description": "As of 17 October 2025, the valuation grade for Stryker Corp. has moved from very expensive to expensive, indicating a slight improvement but still suggesting that the stock is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 25.94, also above typical industry levels. Additionally, the PEG ratio stands at 1.86, suggesting that the stock may not be justified at its current price given its growth prospects.\n\nIn comparison to its peers, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, both indicating that Stryker is trading at a premium relative to these companies. Notably, Stryker's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 3.99% compared to the S&P 500's 13.30%, and a three-year return of 73.64% versus 81.19%..."
      },
      {
        "title": "Stryker Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stryker-corp-valuation-grade-downgraded-from-very-expensive-to-expensive-3640944",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StrykerCorp_valuationdot_3640944.png",
        "date": "2025-10-20 16:59:04",
        "description": "Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a price-to-book value of 7.01. The company’s performance metrics show mixed results compared to the S&P 500, and its valuation is competitive within the Pharmaceuticals and Biotechnology sector."
      },
      {
        "title": "Is Stryker Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stryker-corp-overvalued-or-undervalued-3634429",
        "imagepath": "",
        "date": "2025-10-20 12:22:13",
        "description": "As of 17 October 2025, the valuation grade for Stryker Corp. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 34, a Price to Book Value of 7.01, and an EV to EBITDA of 25.94. \n\nIn comparison to its peers, Stryker's P/E ratio is significantly higher than Abbott Laboratories at 18.36 and Medtronic Plc at 21.47, both of which are considered fairly valued. Additionally, Stryker's PEG ratio of 1.86 suggests that its growth is not adequately reflected in its price compared to peers like Thermo Fisher Scientific, which has a PEG of 2.73. Over the past year, Stryker's stock returned 4.08%, underperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock may be overvalued...."
      },
      {
        "title": "Is Stryker Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stryker-corp-overvalued-or-undervalued-3631968",
        "imagepath": "",
        "date": "2025-10-19 11:59:48",
        "description": "As of 17 October 2025, Stryker Corp. has moved from a very expensive to an expensive valuation grade. The company is currently considered overvalued. Key valuation ratios include a P/E ratio of 34, a Price to Book Value of 7.01, and an EV to EBITDA of 25.94. In comparison, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, highlighting Stryker's relatively high valuation within its peer group.\n\nDespite Stryker's recent stock performance, which has outpaced the S&P 500 over the past week (2.69% vs. 1.70%), its year-to-date and one-year returns of 3.99% and 4.08% respectively, lag behind the S&P 500's returns of 13.30% and 14.08%. This suggests that while the stock has shown some short-term strength, its overall performance is not keeping pace with the broader market, reinforcing the notion of overvaluation...."
      },
      {
        "title": "Stryker Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stryker-corp-forms-death-cross-signaling-potential-bearish-trend-ahead-3626522",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/StrykerCorp_dealthcross_3626522.png",
        "date": "2025-10-16 17:09:48",
        "description": "Stryker Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Current moving averages and MACD indicators reflect a bearish trend, while On-Balance Volume metrics suggest declining momentum. Despite a 3.0% increase over the past year, the stock has faced short-term challenges."
      },
      {
        "title": "Stryker Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/stryker-corp-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3579830",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/StrykerCorp_technicaldot_3579830.png",
        "date": "2025-09-29 16:00:53",
        "description": "Stryker Corp. has recently revised its evaluation amid changing market conditions. The stock is priced at $369.02, reflecting a slight increase from the previous close. Over the past year, Stryker's return has been 2.12%, trailing behind the S&P 500's performance, with current indicators suggesting a mildly bearish sentiment."
      },
      {
        "title": "Is Stryker Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-stryker-corp-technically-bullish-or-bearish-3544996",
        "imagepath": "",
        "date": "2025-09-20 19:00:54",
        "description": "As of 12 September 2025, the technical trend for Stryker Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by weekly and monthly MACD readings, both indicating a bearish outlook. The KST and Dow Theory also reflect a mildly bearish trend on both time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed compared to the S&P 500 over the past week and month, with returns of -2.82% and -0.99% respectively, while the S&P 500 gained 1.05% and 2.33%...."
      }
    ],
    "total": 16,
    "sid": "1161134",
    "stock_news_url": "https://www.marketsmojo.com/news/stryker-corp-1161134"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Stryker Corp. Hits Day Low of $355.75 Amid Price Pressure

2025-11-03 17:36:31

Stryker Corp. faced a significant stock price decline today, marking a challenging trading session. Over the past week and month, the company has experienced notable decreases, contrasting with modest gains in the S&P 500. Despite these challenges, Stryker maintains a strong financial position and robust institutional holdings.

Stryker Corp. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-10-27 15:58:33

Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a Price to Book Value of 7.01. Key financial metrics include an EV to EBIT of 31.29 and a PEG ratio of 1.86, reflecting strong operational efficiency and competitive positioning within the industry.

Is Stryker Corp. overvalued or undervalued?

2025-10-21 12:04:42

As of 17 October 2025, the valuation grade for Stryker Corp. has moved from very expensive to expensive, indicating a slight improvement but still suggesting that the stock is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 25.94, also above typical industry levels. Additionally, the PEG ratio stands at 1.86, suggesting that the stock may not be justified at its current price given its growth prospects. In comparison to its peers, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, both indicating that Stryker is trading at a premium relative to these companies. Notably, Stryker's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 3.99% compared to the S&P 500's 13.30%, and a three-year return of 73.64% versus 81.19%...

Stryker Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape

2025-10-20 16:59:04

Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a price-to-book value of 7.01. The company’s performance metrics show mixed results compared to the S&P 500, and its valuation is competitive within the Pharmaceuticals and Biotechnology sector.

Is Stryker Corp. overvalued or undervalued?

2025-10-20 12:22:13

As of 17 October 2025, the valuation grade for Stryker Corp. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company is currently considered overvalued based on its high valuation ratios, including a P/E ratio of 34, a Price to Book Value of 7.01, and an EV to EBITDA of 25.94. In comparison to its peers, Stryker's P/E ratio is significantly higher than Abbott Laboratories at 18.36 and Medtronic Plc at 21.47, both of which are considered fairly valued. Additionally, Stryker's PEG ratio of 1.86 suggests that its growth is not adequately reflected in its price compared to peers like Thermo Fisher Scientific, which has a PEG of 2.73. Over the past year, Stryker's stock returned 4.08%, underperforming the S&P 500's return of 14.08%, reinforcing the notion that the stock may be overvalued....

Is Stryker Corp. overvalued or undervalued?

2025-10-19 11:59:48

As of 17 October 2025, Stryker Corp. has moved from a very expensive to an expensive valuation grade. The company is currently considered overvalued. Key valuation ratios include a P/E ratio of 34, a Price to Book Value of 7.01, and an EV to EBITDA of 25.94. In comparison, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, highlighting Stryker's relatively high valuation within its peer group. Despite Stryker's recent stock performance, which has outpaced the S&P 500 over the past week (2.69% vs. 1.70%), its year-to-date and one-year returns of 3.99% and 4.08% respectively, lag behind the S&P 500's returns of 13.30% and 14.08%. This suggests that while the stock has shown some short-term strength, its overall performance is not keeping pace with the broader market, reinforcing the notion of overvaluation....

Stryker Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-10-16 17:09:48

Stryker Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Current moving averages and MACD indicators reflect a bearish trend, while On-Balance Volume metrics suggest declining momentum. Despite a 3.0% increase over the past year, the stock has faced short-term challenges.

Stryker Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-09-29 16:00:53

Stryker Corp. has recently revised its evaluation amid changing market conditions. The stock is priced at $369.02, reflecting a slight increase from the previous close. Over the past year, Stryker's return has been 2.12%, trailing behind the S&P 500's performance, with current indicators suggesting a mildly bearish sentiment.

Is Stryker Corp. technically bullish or bearish?

2025-09-20 19:00:54

As of 12 September 2025, the technical trend for Stryker Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by weekly and monthly MACD readings, both indicating a bearish outlook. The KST and Dow Theory also reflect a mildly bearish trend on both time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed compared to the S&P 500 over the past week and month, with returns of -2.82% and -0.99% respectively, while the S&P 500 gained 1.05% and 2.33%....

View All News